LY-104

N/A

Report date: 2025/10/11 11:22:04
NME

Base Information

Drug NameLY-104
Drug Alias NameLY104LY-104
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 4B inhibitors
TargetsPhosphodiesterase 4B
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMarine Biomedical Res Institute Of Qingdao Co LtdOcean University Of ChinaQingdao Haiji Biopharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMarine Biomedical Res Institute Of Qingdao Co Ltd
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A